Shudan Medical Secures Tens of Millions in RMB Funding to Advance Non-Invasive BCI-Powered Digital Therapeutics for Brain Health

Hangzhou Shudan Medical Technology Co., Ltd. (hereinafter referred to as “Shudan Medical”) recently completed a financing round amounting to tens of millions of yuan, with participation from the Shandong Health Fund and ZhenFund. The funds will be primarily used to accelerate the research and development, clinical trials, and market commercialization of innovative digital therapeutic products for both clinical and consumer applications, thereby solidifying the company’s leading position in the field of digital therapeutics for neurodegenerative diseases.

Shudan Medical was founded in 2021 and is based inChina, a global-facing innovative digital therapeutics company dedicated to serving patients in China and around the worldproviding innovative digital therapeutics for brain health that transcend the limitations of traditional medicine and pharmaceuticals.

With socioeconomic progress, population aging has become a global phenomenon driven by the combined effects of low fertility rates and increased life expectancy. Due to its larger population base, China faces a more severe aging challenge. Among various health needs associated with aging, brain disorders—particularly neurodegenerative diseases—represent an area with a significant mismatch between supply and demand. In stark contrast to the rapidly growing number of patients worldwide on the demand side, the supply side has long lacked clinically effective, low-cost, and highly accessible interventions. In recent years, multiple research teams, including those at MIT, have demonstrated that digital therapeutics based on non-invasive brain-computer interface technology exhibit clinical efficacy in halting and reversing various neurological disorders.

Shudan Medical’s self-developed non-invasive brain-computer interface (BCI) digital therapeutic consists of wearable smart hardware and an intelligent digital platform. The wearable smart hardware employs physical stimulation methods while monitoring EEG-based electronic biomarkers, activating the brain’s intrinsic immune system, enhancing connectivity among functional brain regions, and reducing the accumulation of pathological proteins in the brain, thereby achieving the effect of halting or even reversing neurodegenerative processes. Meanwhile, the intelligent digital platform delivers personalized intervention services through evidence-based AI-driven interactive software products and user management services, significantly improving intervention efficacy and user experience.

Dr. Fang Cong, Founder and CEO, holds a Ph.D. in Medicine and Molecular Pharmacology from the University of California, Los Angeles (UCLA), a Master’s degree in Bioengineering from the Massachusetts Institute of Technology (MIT), and an MBA from the MIT Sloan School of Management. She has extensive experience in R&D, management, and commercialization within the healthcare industries of both China and the United States. Prior to founding Shudan, Dr. Fang was a core founder of Yitu Healthcare, where she established and oversaw its global operations. Before joining Yitu, she held positions such as Head of Global Clinical Operations and R&D Scientist at companies including Amgen and Cynvenio Biosystems.

Zhang Shanshan, President of Huiyuan CapitalHuiyuan Capital stated: In 2021, Huiyuan Capital formally established the Shandong Health Equity Investment Platform in collaboration with Shandong Health Group and Xinhua Medical, focusing on the “Smart Technology for Medical Care, Elderly Care, and Wellness” sector. The platform has long been committed to innovative products and services that address the substantial needs of the aging population. Given the global lack of effective treatments for neurodegenerative diseases, we are highly optimistic about Shudan Medical’s portfolio of digital health products tailored to diverse clinical scenarios. We will work hand in hand with Shudan Medical to achieve further milestones and deliver affordable, breakthrough therapeutic solutions to patients.

Xu Jingbo, General Manager of Shandong Health FundIt was stated that Shudan Medical possesses China’s leading non-invasive brain-computer interface (BCI) technology and demonstrates strong innovation and implementation capabilities in the medical technology sector. We are delighted to have the opportunity to collaborate with Shudan Medical, leveraging Shandong Health Group’s extensive resources in healthcare and elderly care industries, to accelerate the deployment and promotion of intelligent brain health solutions.

Fang Ai, Founding Partner and CEO of ZhenFundofIt was stated that Shudan Medical’s core team is a rare multidisciplinary powerhouse in the market, integrating expertise in neuroscience, medicine, engineering, information technology, and intelligent hardware and software. The team boasts years of experience in the research, development, and commercialization of traditional pharmaceuticals, medical devices, and digital health solutions within the realm of medical technology innovation. Furthermore, brain health and brain-computer interfaces represent one of the most promising frontiers in modern science, carrying profound social significance. There is high expectation for Shudan Medical to create even greater social value.

Dr. Fang Cong, CEO of Shudan MedicalStatement: Guided by our original aspiration and conviction in medical innovation, we founded Shudan Medical. Over the past year, the Shudan team has demonstrated strong strategic and execution capabilities. Our self-developed hardware products have obtained national patents, while our software and platform products have been successively launched, with some achieving a complete commercialization loop. In the future, Shudan Medical will uphold its corporate values of “Professionalism, Innovation, and Inclusiveness,” remain user-centric, leverage technology as a means of innovation, serve the broadest user base with the best technologies, and create a new intelligent lifestyle for brain health.

Huiyuan Capital, established in 2019, is a specialized healthcare investment firm focused on value investing in the biopharmaceutical and medical device sectors. Controlled and operated by a market-oriented professional team, it was jointly initiated with state-owned strategic shareholders. The firm systematically invests in high-quality targets possessing breakthrough and innovative technologies within niche segments, and has established in-depth collaborative relationships with multiple industry partners. Adhering to an investment strategy of “industry empowerment + capital support,” Huiyuan Capital aims to deliver long-term, stable investment returns to its investors.

Shandong Health Fund was established in 2021 as a health industry equity investment platform jointly initiated by Huiyuan Capital, Shandong Healthcare Industry Development Group Co., Ltd. (“Shandong Health Group”), and Xinhua Medical (600687.SH). The inaugural fund is themed around “Smart Technology for Medical Care, Elderly Care, and Rehabilitation,” focusing on innovative therapeutic technologies, novel pharmaceuticals and medical devices, and smart healthcare and elderly care services that meet the needs of populations requiring medical and rehabilitative care. By leveraging an industry-investment synergy model, the fund fully utilizes the extensive industrial resources of Shandong Health Group and Xinhua Medical in the fields of elderly care and healthcare to deeply empower high-quality enterprises.

ZhenFund is an early-stage investment firm co-founded by Mr. Xu Xiaoping and Mr. Wang Qiang in partnership with Sequoia Capital China in 2011, with total assets under management exceeding RMB 10 billion. Since its inception, ZhenFund has been actively seeking out the most exceptional entrepreneurial teams and epoch-defining investment opportunities in fields such as future technologies, artificial intelligence, enterprise services, healthcare, consumer sectors, and mobile internet.

Headquartered in Beijing, ZhenFund has successively expanded its presence to Shanghai and Shenzhen. The original aspiration of Mr. Xu Xiaoping and Mr. Wang Qiang in founding ZhenFund was to “identify truly outstanding entrepreneurs and build great companies that lead technological innovation and change the world.” ZhenFund’s cultural values—emphasizing integrity, friendliness and humility, approachability and warmth, professional efficiency, and idealism—have earned recognition and acclaim from entrepreneurs both in China and abroad.